AbbVie 12-Month Average Price Target Raised to $291
TradingView reports AbbVie's average 12-month price target rose to $291 from $289.08, based on estimates from 26 analysts, with the consensus still at Buy.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, citing FactSet data, the average 12-month price target for AbbVie shares rose from $289.08 to $291. Estimates from 26 analysts range between $230 and $350 per share.
The consensus rating stays at Buy: of the 32 analysts covering the company, 24 rate it Buy, 7 Hold and 1 Sell.
why it matters
Updates like this reflect revised analyst expectations and appear regularly, so their direct market impact is usually limited. For investors they offer a snapshot of sentiment toward the drugmaker's stock, not a signal to act or a forecast of its price.
tags
instruments
sources
- AbbVie Inc. Stock 12‑Month Price Target Raised to $291 — TradingView, 30 October 2026 at 22:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗